CHICAGO – Detailed data from the IMvigor 210 study that led to the accelerated approval of Tecentriq (atezolizumab, Genentech Inc./ Roche AG), presented over the weekend, showed impressive benefits of the drug. The case for the complementary diagnostic approved along with it, however, was decidedly more mixed.